ILDSTAD SUZANNE (Chief Scientific Officer) sold 14.6% of their position (525K shares) of TOURMALINE BIO, INC. on the open market
Open‑market sale worth $1.47M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/23/2022ACC: 0000899243-22-029561
DirectorOfficer10% Owner· Chief Scientific Officer
Since May 2021
-525K
Net shares
Net seller
$1.47M
Total sold
1
Open market trades
0B · 1S
1
Total transactions
525K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−525K
Price / share
$2.80
Trade value
$1.47M
% of position
14.6%
8/22/2022
3.61M→3.08M
Total
Net shares
−525K
Net value
-$1.47M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/22/2022 | S · Sale | −525K | $2.80 | $1.47M | 14.6% | 3.61M | 3.08M |
| Total | −525K | -$1.47M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)3
Common Stock
IndirectShares owned654.21K
Common Stock
IndirectShares owned654.21K
Common Stock
IndirectShares owned1.20M
Total
2.51M indirect2.51M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 654.21K | Indirect |
| Common Stock | 654.21K | Indirect |
| Common Stock | 1.20M | Indirect |
| Total | 2.51M | 2.51M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported